thalidomide has been researched along with tretinoin in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (14.29) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, Y; Katayama, R; Miyachi, H; Naito, M; Noguchi, T | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Becerra, JE; Cordero, JF; Erickson, JD; Khoury, MJ | 1 |
| Holtzman, NA; Khoury, MJ | 1 |
| Adams, MM; Erickson, JD; Khoury, MJ; Rhodes, P | 1 |
| Golbus, MS; Goldberg, JD | 1 |
| Johnson, EM | 1 |
| Yarchoan, R | 1 |
| Bilgrami, S; Bona, RD; de Medeiros , BC; Edwards, RL; Feingold, JM; Rezuke, WN; Ricci, A; Shen, PU; Tsongalis, G; Tutschka, PJ | 1 |
| Otsuki, T; Sugihara, T; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
| Dannat, K; Dingermann, T; Eger, K; Tillner, J; Weiss, M; Winckler, T | 1 |
| Hashimoto, Y; Kobayashi, H; Makishima, M; Miyachi, H; Noguchi, T; Shinji, C | 1 |
| Avilés, A; Castañeda, C; Cleto, S; González, M; Huerta-Guzmán, J; Nambo, MJ; Neri, N; Talavera, A | 1 |
| Balasubramanian, L; Evens, AM | 1 |
| Dai, CW; Pei, MF; Shen, JK; Xu, YX; Zhang, GS; Zheng, WL | 1 |
| Zeller, R | 1 |
| Benvenisty, N; Mayshar, Y; Yanuka, O | 1 |
| Baladandayuthapani, V; Bjorklund, CC; Jones, RJ; Kuiatse, I; Lin, HY; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, H; Wang, M; Weber, DM; Yang, J | 1 |
| Herskind, C; Maier, P; Milanović, D; Schanne, DH; Wenz, F | 1 |
| Asakura, H | 1 |
| Alonso, S; Ganguly, S; Ghiaur, G; Jones, JW; Jones, RJ; Kane, MA; Su, M | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Kalisch-Smith, JI; Sparrow, DB; Ved, N | 1 |
| Bunce, CM; Drayson, MT; Khanim, FL | 1 |
7 review(s) available for thalidomide and tretinoin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapy for Kaposi's sarcoma: recent advances and experimental approaches.
Topics: Administration, Oral; Alitretinoin; Anthracyclines; Antineoplastic Agents; Cyclohexanes; Humans; Immunosuppressive Agents; Liposomes; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sarcoma, Kaposi; Sesquiterpenes; Thalidomide; Tretinoin | 1999 |
Targeting angiogenesis for the treatment of sarcoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Sarcoma; Sarcoma, Kaposi; Thalidomide; Tretinoin; Vascular Endothelial Growth Factor A | 2006 |
The temporal dynamics of vertebrate limb development, teratogenesis and evolution.
Topics: Animals; Biological Evolution; Body Patterning; Extremities; Gene Expression Regulation, Developmental; Hedgehog Proteins; Limb Buds; Signal Transduction; Teratogens; Thalidomide; Tretinoin; Vertebrates | 2010 |
[Thrombosis and DIC in hematological malignancies].
Topics: Annexin A2; Antineoplastic Agents; Asparaginase; Cytokines; Disseminated Intravascular Coagulation; Drug Interactions; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Thalidomide; Thrombomodulin; Tretinoin; Venous Thromboembolism | 2014 |
Environmental Risk Factors for Congenital Heart Disease.
Topics: Alcohol Drinking; Animals; Diabetes Mellitus; Environmental Exposure; Gene-Environment Interaction; Genomics; Heart; Heart Defects, Congenital; Humans; Hyperthermia; Hypoxia; Obesity; Phenylketonurias; Prevalence; Risk Factors; Thalidomide; Tretinoin; Vitamin A | 2020 |
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin | 2022 |
2 trial(s) available for thalidomide and tretinoin
| Article | Year |
|---|---|
Novel therapy in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Male; Multiple Myeloma; Recombinant Proteins; Thalidomide; Tretinoin | 2005 |
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Risk Factors; Thalidomide; Treatment Outcome; Tretinoin | 2008 |
19 other study(ies) available for thalidomide and tretinoin
| Article | Year |
|---|---|
Cell differentiation inducers derived from thalidomide.
Topics: Antineoplastic Agents; Cell Differentiation; Drug Screening Assays, Antitumor; Flow Cytometry; HL-60 Cells; Humans; Indoles; Isoindoles; Leukemia; Lipopolysaccharide Receptors; Structure-Activity Relationship; Thalidomide | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Clinical-epidemiologic assessment of pattern of birth defects associated with human teratogens: application to diabetic embryopathy.
Topics: Abnormalities, Drug-Induced; Congenital Abnormalities; Diabetes Mellitus, Type 1; Female; Georgia; Humans; Infant, Newborn; Pregnancy; Pregnancy in Diabetics; Rubella Syndrome, Congenital; Sensitivity and Specificity; Thalidomide; Tretinoin | 1989 |
On the ability of birth defects monitoring to detect new teratogens.
Topics: Abnormalities, Drug-Induced; Epidemiologic Methods; Humans; Infant, Newborn; Isotretinoin; Risk; Teratogens; Thalidomide; Tretinoin; Valproic Acid | 1987 |
Monitoring for multiple malformations in the detection of epidemics of birth defects.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Biometry; Female; Humans; Pregnancy; Rubella; Teratogens; Thalidomide; Tretinoin; United States | 1987 |
The value of case reports in human teratology.
Topics: Abnormalities, Drug-Induced; Animals; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Erythromycin; Female; Humans; Infant, Newborn; Isotretinoin; Medical Records; Pregnancy; Publishing; Pyridoxine; Teratogens; Thalidomide; Tretinoin; Warfarin | 1986 |
A risk assessment of topical tretinoin as a potential human developmental toxin based on animal and comparative human data.
Topics: Abnormalities, Drug-Induced; Administration, Topical; Animals; Female; Humans; Isotretinoin; Keratolytic Agents; Methotrexate; Pregnancy; Risk Assessment; Teratogens; Thalidomide; Tretinoin; Valproic Acid | 1997 |
Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Topics: Administration, Oral; Administration, Topical; Adult; Alitretinoin; Antineoplastic Agents; Child; Female; Hematopoietic Stem Cell Transplantation; Herpesvirus 8, Human; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Sarcoma, Kaposi; Thalidomide; Tretinoin | 2000 |
Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Diphosphonates; Drug Synergism; Humans; Imidazoles; Interferon-alpha; Interphase; Multiple Myeloma; RNA; Thalidomide; Tretinoin; Tumor Cells, Cultured | 2002 |
Effects of medicinal compounds on the differentiation of the eukaryotic microorganism dictyostelium discoideum: can this model be used as a screening test for reproductive toxicity in humans?
Topics: Animals; Culture Media; Dictyostelium; Diethylstilbestrol; Drug Evaluation, Preclinical; Gene Expression Regulation; Genes, Reporter; Models, Biological; Phenytoin; Reproduction; Teratogens; Thalidomide; Tretinoin | 2003 |
Enhancement of all-trans retinoic acid-induced HL-60 cell differentiation by thalidomide and its metabolites.
Topics: Cell Differentiation; Drug Synergism; HL-60 Cells; Humans; Thalidomide; Tretinoin | 2005 |
Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells.
Topics: Cell Differentiation; Cell Line; Embryoid Bodies; Embryonic Stem Cells; Endoderm; Ethanol; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Induced Pluripotent Stem Cells; Neurogenesis; Teratogens; Thalidomide; Tretinoin | 2011 |
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Humans; Hyaluronan Receptors; Hyaluronic Acid; Immunologic Factors; Lenalidomide; Mice; Multiple Myeloma; Protein Binding; Thalidomide; Tretinoin; Xenograft Model Antitumor Assays | 2014 |
The influence of retinoic Acid and thalidomide on the radiosensitivity of u343 glioblastoma cells.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neoplastic Stem Cells; Radiation Tolerance; Thalidomide; Tretinoin; Tumor Stem Cell Assay | 2014 |
Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Lenalidomide; Mesenchymal Stem Cells; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thalidomide; Tretinoin; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |